U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07076186) titled 'Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS' on July 14.
Brief Summary: The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.
Study Start Date: Dec. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Uterine Leiomyosarcoma
Intervention:
DRUG: Trabectedin
Given by IV Infusion
DRUG: Doxorubicin Hydrochloride
Given by IV Infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curat...